TABLE 2

FROM:

Loss of BMI-1 expression is associated with clinical progress of malignant melanoma

Ingeborg M Bachmann, Hanne E Puntervoll, Arie P Otte and Lars A Akslen

Table 2. Estimated 5- and 10-year survival rates for patients with vertical growth phase melanoma (product-limit method) by clinico-pathological variables, p16 and BMI-1 using death from melanoma as end point

Variables	No. of cases	Estimated survival rates (% )		P-value a
		5 years	10 years
Tumor thickness				0.0001
3.6 mmb	101	79	73
>3.6 mm	101	55	42
Level of invasion				<0.0001
II–V	166	72	62
V	35	40	32
Ulceration				0.0039
Absent	114	76	67
Present	83	56	44
Vascular invasion				0.0001
Absent	162	73	60
Present	40	39	39
Ki-67 expression				<0.0001
16% c	49	89	85
>16%	138	59	47
p16 expression				0.0003
Absent/minimald	85	51	37
Moderate/strong	105	77	67
CDK4 expression				0.024
Weakc	26	47	35
Strong	113	68	55
p14 expression				0.52
Weake	54	61	68
Strong	92	51	53
BMI-1 (F6)				0.043
Weake	95	56	43
Strong	32	75	75
BMI-1 (C69)				0.006
Weake	79	51	37
Strong	27	83	77

^a Log-rank test.

^b Median value.

^c Cut-point lower quartile.

^d SI1.

^e Cut-point median SI.